Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23855474 | 0.98 | CA2 (0.58) | CA12CA2CA1CA7CA14 | |
| SCHEMBL6534021 | 0.88 | CA12 (0.68) | CA12CA2CA1CA7CA14 | |
| SCHEMBL13770963 | 0.86 | CA2 (0.53) | CA12CA2CA1CA7CA14 | |
| SCHEMBL4901848 | 0.84 | CA2 (0.64) | CA12CA2CA1CA7CA14 | |
| SCHEMBL393081 | 0.83 | CA2 (0.63) | CA12CA2CA1CA7CA14 | |
| SCHEMBL8298646 | 0.83 | CA2 (0.58) | CA12CA2CA1CA7CA14 | |
| SCHEMBL10371769 | 0.81 | MEN1 (0.53) | CA12CA2CA1ALDH1A1LMNA | |
| SCHEMBL15178402 | 0.81 | CA2 (0.53) | CA12CA2CA1CA7CA14 | |
| SCHEMBL24990593 | 0.81 | CA12 (0.59) | CA12CA2CA1CA7CA14 | |
| SCHEMBL11690253 | 0.81 | CA12 (0.59) | CA12CA2CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | claimed |
| US-4022759-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | claimed |
| US-4022761-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | claimed |
| US-7638638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1625122-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022761-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022759-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022759-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022761-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | CA12 1088/4885CA2 2105/4885CA1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.